Immunotherapies Continue to Impress in NSCLC Trials With Several Forecast for Approval
November 10th 2014Roy S. Herbst, MD, PhD, led some of the first trials of gefitinib, the EGFR inhibitor that helped introduce targeted therapies of this important mutation into the treatment landscape of non–small cell lung cancer.
Lung Cancer Treatment on Brink of New Molecular Era
November 10th 2014Although testing for EGFR mutations and ALK rearrangements in patients with NSCLC has become widespread, the time has come to translate into clinical practice next-generation sequencing assays that provide exponentially more information about tumor biology.
Dr. Levy Discusses Recent Updates in Immunotherapy for Lung Cancer
November 10th 2014Benjamin P. Levy, MD, director, Thoracic Medical Oncology, Mount Sinai Beth Israel, associate director, Cancer Clinical Trials Office, Mount Sinai Hospital, Mt. Sinai School of Medicine, discusses new data on immunotherapy for lung cancer.
Dr. Arcila on the Benefits of New Molecular Diagnostic Platforms for the Treatment of Lung Cancer
November 10th 2014Maria E. Arcila, MD, acting director, Diagnostic Molecular Pathology Laboratory, Memorial Sloan Kettering Cancer Center, discusses the benefits of new molecular diagnostic platforms for the treatment of lung cancer.
PER Conference Features Expert Views on Lung Cancer Advances
November 7th 2014Lung cancer experts provided insights into recent developments in the treatment of the disease, covering topics ranging from resistance to targeted therapies to immunotherapy agents under study, during the 9th Annual New York Lung Cancer Symposium in New York City.
Dr. Shaw on Monitoring Crizotinib-Related Side Effects
November 10th 2013Alice T. Shaw, MD, PhD, an attending physician in the Center for Thoracic Cancers at Massachusetts General Hospital, discusses monitoring adverse events associated with crizotinib when treating patients with ALK-positive lung cancer
NY Symposium Tackles Emerging Agents, Pressing Questions in Lung Cancer
November 8th 2013Leaders in thoracic medical oncology from major cancer centers will come together Saturday to discuss advances in the field of lung cancer treatment during the 8th Annual New York Lung Cancer Symposium® in New York City.